HIV Prevention

Medicare Beneficiaries Can Now Access PrEP Without Cost-Sharing

“We commend the Biden-Harris administration for increasing PrEP uptake using all the tools at its disposal. Patient cost-sharing has been a significant barrier for Medicare beneficiaries. With this new NCD, people on Medicare can join those with private insurance who can access PrEP without cost-sharing. Now we have to make sure these policies are properly implemented and enforced,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

read more

Senate appropriators maintain funding for domestic HIV & hepatitis programs

“We sincerely thank Senate Labor HHS Appropriations Subcommittee Chair Tammy Baldwin and Ranking Member Shelley Moore Capito and their colleagues for demonstrating their continued commitment to ending HIV in the United States. While working within the confines of an extremely restrictive budget, they crafted a spending bill that prioritizes the domestic response to HIV,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “However, given that the House version of the bill includes sizeable funding cuts, program eliminations and divisive policy riders, we realize passage of this spending bill is far from reality. House Republicans must come to the table and support bills, such as this one, that can pass the Congress and be signed by the President.”

read more

63 HIV organizations urge Biden administration to require insurers to cover long-acting PrEP without cost-sharing

“Long-acting PrEP can be the answer to low PrEP uptake, particularly in the communities not using PrEP today. The Biden administration has an opportunity to ensure that people with private insurance can access PrEP now and into the future, free of any cost-sharing, with properly worded guidance to insurers,” commented Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute. “Poor PrEP uptake among various racial and ethnic groups is an example of failed healthcare decisions of the past. CMS can help correct these inequities by requiring insurers nationwide to cover all FDA-approved PrEP drugs, without burdensome prior authorizations, and begin the vigorous enforcement of ACA protections that has been lacking to date.”

read more

House proposes to gut ending HIV programs—again

“Instead of providing new investments in ending HIV by increasing funding for testing, prevention programs, such as PrEP, and life-saving care and treatment, House Republicans are again choosing to go through a worthless exercise of cutting programs that the American people depend on and will never pass,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “These were purposeful decisions that are well below the agreed-upon budget caps. While we will vigorously fight these cuts, we look forward to working with the entire Congress in a bipartisan fashion on spending bills that can actually become law.”

read more

New CDC HIV Data Demonstrates the Impact of Flat Funding

While we would have liked to see improved outcomes, federal funding for CDC HIV prevention and the Ryan White HIV/AIDS care and treatment program, along with other critical programs, has remained flat for years. The only increases have been for the Ending the HIV Epidemic initiative, and even that program hasn’t received the increases it needs to be successful,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Without significant increases for care and treatment, and prevention programs, including those for PrEP, sadly we will continue to experience only small drops in the number of new diagnoses, and racial and ethnic disparities will persist. As a nation, we can and must do better.”

read more

Pin It on Pinterest